torsades de pointes

(redirected from torsades)
Also found in: Dictionary, Encyclopedia.

torsades de pointes

 [tor-sahd´ duh pwahnt]
an atypical rapid ventricular tachycardia with periodic waxing and waning of amplitude of the QRS complexes on the electrocardiogram. It is usually drug related and may be either self-limiting or progressing to ventricular fibrillation.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
References in periodicals archive ?
While sotalol administration increases iCEB and causes torsade de Pointes (TdP), flecainide usage decreases iCEB and causes non-TdP ventricular tachycardia or ventricular fibrillation (10).
Viskin, "Long QT syndromes and torsade de pointes," The Lancet, vol.
Several case reports showed that donepezil could lead rarely to serious bradycardia needing pacemaker implantation and fatal ventricular arrhythmia (torsade de pointes (TdP)) [7,8].
Monomorphic VT occur in 83 (65.35%), polymorphic VT occurred in 19 (14.96%), torsade depointes in 9 (7.08%) and ventricular fibrillation in 16 (12.6%) patients.
[1] Another effect of arsenic is that it can cause QT interval prolongation and can even result in life-threatening ventricular arrhythmia, torsades de pointes, which is can even lead to cardiac death.
Anderson, "Antipsychotic-related QTc prolongation, torsade de pointes and sudden death," Drugs, vol.
Murphy, "QT prolongation and torsades de pointes after administration of FK506," Transplantation, vol.
Electrocardiography abnormalities such as atrial flutter, atrioventricular block, torsade de pointes, sinus tachycardia, QT prolongation, ST elevation, and T wave inversion were detected in seven patients.
Torsades de pointes associated with fluoroquinolones.
These can include arrhythmias such as Torsades de Pointes and Ventricular Fibrillation, which may ultimately lead to death.
Drug induced prolongation of QTc interval has become the first cause of withdrawal or restricted use of the drug in the past years because of potential risk of life threatening polymorphic ventricular tachycardia and torsades de pointes.